Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY900014-U200 · 2 trials · 1 indication
Pharmacokinetics (PK): Insulin Lispro AUC time zero to 10 hours.
Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC\[0-10h\])
| Arm | Type | Description |
|---|---|---|
| LY900014 U-200 | EXPERIMENTAL | Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods. |
| LY900014 U-100 | EXPERIMENTAL | Single SC dose of LY900014 U-100 in two of four study periods. |
| LY900014-U200 | EXPERIMENTAL | Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods |
| LY900014-U100 | EXPERIMENTAL | Single SC dose of 15 U LY900014 U-100 in two of four study periods |
| Name | Type | Description |
|---|---|---|
| LY900014 U-200 | DRUG | Administered SC |
| LY900014 U-100 | DRUG | Administered SC |
| LY900014-U200 | DRUG | Administered SC |
| LY900014-U100 | DRUG | Administered SC |
Inclusion Criteria: \- Healthy male or a female (not pregnant and agreeable to take birth control measures until study completion) * Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²) * Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laborat...
LY900014-U200 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with two completed trials evaluating the drug in healthy volunteers. The drug is not approved and remains under investigation.
LY900014-U200 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy participants.
LY900014-U200 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy participants. The drug is investigational and has not been approved for any use.
LY900014-U200 has been studied in two completed Phase 1 trials: NCT03334448, which enrolled 49 healthy participants, and NCT03616977, which enrolled 69 healthy participants. Both trials were conducted in Singapore and compared two formulations of the drug.
LY900014-U200 is a designation for a specific formulation or version of the drug LY900014. The clinical trials listed for LY900014-U200 compare two formulations of LY900014 in healthy participants, indicating that LY900014-U200 is one of the formulations being tested.